June 2019 - Volume 3 - Issue - Contributor Index

Author:
Qayed, M.

TISAGENLECLEUCEL APPEARS EFFECTIVE AND SAFE IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA WITH HIGH-RISK CYTOGENETIC ABNORMALITIES: S1618

Grupp, S.; Maude, S.; Baruchel, A.; More

HemaSphere. 3:746-747, June 2019.

Author:
Qayum, N.
Author:
Qazilbash, M.

POST-TRANSPLANT CYCLOPHOSPHAMIDE IN HLA MATCHED AND HAPLOIDENTICAL TRANSPLANT RECIPIENTS RECEIVING MYELOABLATIVE TIMED SEQUENTIAL BUSULFAN CONDITIONING REGIMEN: RESULTS OF A PHASE II STUDY: PS1530

Mehta, R.; Bassett, R.; Olson, A.; More

HemaSphere. 3:706, June 2019.

RITUXIMAB-BEAM AND AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) FOR PATIENTS (PTS) WITH RELAPSED FOLLICULAR LYMPHOMA (FL) NOT ABLE TO RECEIVE AN ALLOGENEIC SCT: 8-YEAR MEDIAN FOLLOW-UP RESULTS: PS1561

Khouri, I.; Milton, D.; Young, K.; More

HemaSphere. 3:720, June 2019.

Author:
Qi, B.-Q.

CONSISTENCY OF GENOMIC ALTERATIONS ASSESSED BY NEXT-GENERATION SEQUENCING AMONG CIRCULATING TUMOR DNA, BONE MARROW AND PERIPHERAL BLOOD MONONUCLEAR CELLS IN PEDIATRIC AML: PF233

Ruan, M.; Liu, C.; Qi, B.-Q.; More

HemaSphere. 3:69, June 2019.

Author:
Qi, M.

EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (D-RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF POLLUX BASED ON CYTOGENETIC RISK: PF591

Dimopoulos, M. A.; San-Miguel, J.; White, D.; More

HemaSphere. 3:247-248, June 2019.

IMPACT OF AGE ON EFFICACY AND SAFETY OF DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (D-RD) IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): MAIA: PF592

Hulin, C.; Facon, T.; Kumar, S.; More

HemaSphere. 3:248-249, June 2019.

EFFICACY AND SAFETY OF DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (D-VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF CASTOR BASED ON CYTOGENETIC RISK: PF596

Weisel, K.; Spencer, A.; Lentzsch, S.; More

HemaSphere. 3:251, June 2019.

RANDOMIZED, OPEN-LABEL, NON-INFERIORITY, PHASE 3 STUDY OF SUBCUTANEOUS (SC) VERSUS INTRAVENOUS (IV) DARATUMUMAB (DARA) ADMINISTRATION IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: COLUMBA: S823

Mateos, M.-V.; Nahi, H.; Legiec, W.; More

HemaSphere. 3:364, June 2019.

UPDATED RISK STRATIFICATION MODEL FOR SMOLDERING MULTIPLE MYELOMA (SMM) INCORPORATING THE REVISED IMWG DIAGNOSTIC CRITERIA: PS1349

Mateos, M.-V.; Kumar, S.; Gonzalez, V.; More

HemaSphere. 3:616, June 2019.

Author:
Qian, J.
Author:
Qin, X.
Author:
Qin, Y.-Z.

INCIDENCE, RISK FACTORS AND OUTCOMES OF SINUSOIDAL OBSTRUCTION SYNDROME AFTER HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION: PB2361

Cai, X.; Wu, J.; Gui, R.-Y.; More

HemaSphere. 3:1052, June 2019.

Author:
Qiu, A.
Author:
Qiu, H.
Author:
Qiu, L.
Author:
Qiu, L.-G.
Author:
Quach, H.

IMPACT OF AGE ON EFFICACY AND SAFETY OF DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (D-RD) IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): MAIA: PF592

Hulin, C.; Facon, T.; Kumar, S.; More

HemaSphere. 3:248-249, June 2019.

EFFICACY AND SAFETY OF DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (D-VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF CASTOR BASED ON CYTOGENETIC RISK: PF596

Weisel, K.; Spencer, A.; Lentzsch, S.; More

HemaSphere. 3:251, June 2019.

THE AUSTRALASIAN LEUKAEMIA AND LYMPHOMA (ALLG) GROUP MM17 TRIAL: RESPONSE ADAPTIVE SALVAGE WITH CARFILZOMIB-THALIDOMIDE-DEXAMETHASONE FOR MULTIPLE MYELOMA PATIENTS FAILING FRONT-LINE BORTEZOMIB: PF604

Spencer, A.; Quach, H.; Horvath, N.; More

HemaSphere. 3:255-256, June 2019.

ANTITUMOR ACTIVITY OF PEMBROLIZUMAB PLUS DINACICLIB IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA: THE PHASE 1B KEYNOTE-155 STUDY: PS1075

Gregory, G.; Walker, P.; Mahadevan, D.; More

HemaSphere. 3:487, June 2019.

Author:
Quadvlieg, D.
Author:
Quah, C.
Author:
Quan, M.
Author:
Quaresmini, G.
Author:
Quarta, A.
Author:
Quarta, C.

BORTEZOMIB-HIGH DOSE METHYLPREDNISOLONE OFFERS IMPROVED HAEMATOLOGICAL RESPONSES AND OVERALL SURVIVAL COMPARED TO BORTEZOMIB-DEXAMETHASONE IN SYSTEMIC LIGHT CHAIN AMYLOIDOSIS: PB2127

Mahmood, A. S.; Sachchithanantham, S.; Harrison, S.; More

HemaSphere. 3:958, June 2019.

Author:
Quattrone, M.
Author:
Queirós, A.

THE PROLIFERATIVE HISTORY SHAPES THE DNA METHYLOME OF B-CELL TUMORS AND PREDICTS CLINICAL OUTCOME: S843

Duran-Ferrer, M.; Clot, G.; Nadeu, F.; More

HemaSphere. 3:376, June 2019.

Author:
Queizán, J. A.

SYNTHETIC LETHAL EFFECTS OF DUAL BCR AND PARP INHIBITION IN PROLIFERATIVE DEL(11Q) CLL CELLS IN THE PRESENCE OF STROMAL STIMULATION: S896

Quijada-Álamo, M.; Hernández-Sánchez, M.; Rodríguez-Vicente, A. E.; More

HemaSphere. 3:403-404, June 2019.

A NOVEL REFINED PROGNOSTIC MODEL FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS COMBINING IGH TRANSLOCATIONS AND NEXT-GENERATION SEQUENCING: PF357

Pérez-Carretero, C.; Hernández-Sánchez, M.; González-Martínez, T.; More

HemaSphere. 3:130-131, June 2019.

Author:
Quek, L.

A PHASE 1B/2 CLINICAL STUDY OF TARGETED IDH1 INHIBITION WITH IVOSIDENIB, IN COMBINATION WITH THE BCL-2 INHIBITOR VENETOCLAX, FOR PATIENTS WITH IDH1-MUTATED (MIDH1) MYELOID MALIGNANCIES: PF291

Dinardo, C.; Takahashi, K.; Kadia, T.; More

HemaSphere. 3:97, June 2019.

Author:
Quenet, S.

A PHASE 2 STUDY OF NILOTINIB (NIL) IN PEDIATRIC PATIENTS (PTS) WITH PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (CML): SAFETY UPDATE AFTER 36 CYCLES OF TREATMENT: PF412

Hijiya, N.; Maschan, A.; Colombini, A.; More

HemaSphere. 3:158, June 2019.

Author:
Querol, L.
Author:
Quesada, M.

SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGIC NEOPLASM, EVOLVING TO SIMULTANEOUS CD33 POSITIVE MAST CELL LEUKEMIA AND ACUTE MYELOID LEUKEMIA, TREATED WITH GEMTUZUMAB-OZOGAMICIN: PB2230

López-Pereira, P.; Figuera, Á.; Ormazábal, I.; More

HemaSphere. 3:999-1000, June 2019.

SAFETY AND EFFECTIVENESS OF CHLORAMBUCIL-OBINUTUZUMAB IN THE FRONT LINE TREATMENT OF UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: REAL-LIFE DATA FROM ANDALUSIAN LYMPHOID NEOPLASM GROUP (GRANEL): PB1898

Puerta, Puerta J.M.; Palanco, Martín V.; Badiola, J.; More

HemaSphere. 3:865, June 2019.

Author:
Quesnel, B.

TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH IDH2-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA - A FRENCH MEDICAL CHART REVIEW ANALYSIS: PS1041

Pigneux, A.; Quesnel, B.; Thomas, X.; More

HemaSphere. 3:470-471, June 2019.

Author:
Quezada, S. A.
Author:
Quick, D.

HEALTH-RELATED QUALITY OF LIFE WITH POMALIDOMIDE + LOW-DOSE DEXAMETHASONE + DARATUMUMAB IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA AFTER LENALIDOMIDE TREATMENT: PF631

Reece, D.; Bahlis, N. J.; Samaras, C.; More

HemaSphere. 3:268-269, June 2019.

Author:
Quiery, A. T.

AVAPRITINIB, A POTENT AND SELECTIVE INHIBITOR OF KIT D816V, INDUCES COMPLETE AND DURABLE RESPONSES IN PATIENTS (PTS) WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM): S830

Radia, D.; Deininger, M. W.; Gotlib, J.; More

HemaSphere. 3:368, June 2019.

A NOVEL REFINED PROGNOSTIC MODEL FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS COMBINING IGH TRANSLOCATIONS AND NEXT-GENERATION SEQUENCING: PF357

Pérez-Carretero, C.; Hernández-Sánchez, M.; González-Martínez, T.; More

HemaSphere. 3:130-131, June 2019.

SYNTHETIC LETHAL EFFECTS OF DUAL BCR AND PARP INHIBITION IN PROLIFERATIVE DEL(11Q) CLL CELLS IN THE PRESENCE OF STROMAL STIMULATION: S896

Quijada-Álamo, M.; Hernández-Sánchez, M.; Rodríguez-Vicente, A. E.; More

HemaSphere. 3:403-404, June 2019.

Author:
Quilichini, B.

B-CELL PROLYMPHOCYTIC LEUKEMIA (B-PLL) AND PROLYMPHOCYTOID MANTLE CELL LYMPHOMA (PMCL) (MORE THAN 55% OF PROLYMPHOCYTES) ARE CLOSED BUT DISTINCT ENTITIES. ON BEHALF GFCH AND FILO GROUPS: PB1868

Chapiro, E.; Diop, K.; Dessen, P.; More

HemaSphere. 3:851-852, June 2019.

Author:
Quint, K. D.

MOLECULAR ANALYSIS OF PRIMARY CUTANEOUS DIFFUSE LARGE B-CELL LYMPHOMA LEG TYPE AT DIAGNOSIS AND RELAPSE - IMPLICATIONS FOR TARGETED THERAPIES: PF509

Schrader, A. M. R.; de Groen, R. A. L.; Willemze, R.; More

HemaSphere. 3:207-208, June 2019.

Author:
Quintana, G.

IBRUTINIB, SINGLE AGENT BTK INHIBITOR, FOR RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA: A REAL-WORLD EXPERIENCE FROM RETE EMATOLOGICA PUGLIESE (REP).: PB1901

Scalzulli, P. R.; Guarini, A.; Loseto, G.; More

HemaSphere. 3:866-867, June 2019.

Author:
Quintarelli, C.

ACADEMIC, PHASE1 TRIAL ON T CELLS EXPRESSING BOTH CD19 CHIMERIC ANTIGEN RECEPTOR AND INDUCIBLE CASPASE 9 SAFETY SWITCH FOR TREATMENT OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKAEMIA AND NON-HODGKIN LYMPHOMA: S1635

Del Bufalo, F.; Merli, P.; Vinti, L.; More

HemaSphere. 3:755, June 2019.

Author:
Quintero, G.
Author:
Quinto, A. M.

REAL-WORLD ITALIAN EXPERIENCE OF POMALIDOMIDE IN RELAPSED-REFRACTORY MYELOMA: RETROSPECTIVE MULTICENTER STUDY BY THE RETE EMATOLOGICA PUGLIESE AND BASILICATA: PB2130

Mele, G.; Pastore, D.; Di Renzo, N.; More

HemaSphere. 3:959, June 2019.

Author:
Quiroga, L.

OUTCOME IN TRANSPLANT ELIGIBLE PATIENTS WITH MULTIPLE MYELOMA IN LATIN AMERICA. AN INTERNATIONAL STUDY OF GELAMM: PS1402

Peña, C.; Schutz, N. P.; Bove, V.; More

HemaSphere. 3:643-644, June 2019.

Author:
Quota, A.
Author:
Quraishy, M.
Author:
Quraishy, M. S.
Show: